GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embecta Corp (FRA:JX7) » Definitions » Cash, Cash Equivalents, Marketable Securities

Embecta (FRA:JX7) Cash, Cash Equivalents, Marketable Securities : €276 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Embecta Cash, Cash Equivalents, Marketable Securities?

Embecta's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 (€305.93 Mil) to Dec. 2023 (€273.91 Mil) but then increased from Dec. 2023 (€273.91 Mil) to Mar. 2024 (€275.82 Mil).

Embecta's annual cash, cash equivalents, marketable securities increased from Sep. 2021 (€0.00 Mil) to Sep. 2022 (€334.21 Mil) but then declined from Sep. 2022 (€334.21 Mil) to Sep. 2023 (€305.93 Mil).


Embecta Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Embecta's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Embecta Cash, Cash Equivalents, Marketable Securities Chart

Embecta Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23
Cash, Cash Equivalents, Marketable Securities
- - - 334.21 305.93

Embecta Quarterly Data
Sep19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 323.54 292.96 305.93 273.91 275.82

Embecta Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Embecta  (FRA:JX7) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Embecta Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Embecta's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Embecta (FRA:JX7) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embecta Corp (FRA:JX7) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
Address
300 Kimball Drive, Suite 300, Parsippany, NJ, USA, 07054
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.

Embecta (FRA:JX7) Headlines

No Headlines